Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLAL PRED vs prednisolone in moderate acute ulcerative colitis
2004-005032-35Phase 3Completed
- Sponsor
- Alizyme Therapeutics
- Start
- Feb 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prednisolone sodium metasulfobenzoate in autoimmune colitis (2 arms), sponsored by Alizyme Therapeutics. Primary endpoints: Clinical Improvement and Early Morning Plasma Cortisol. Started Feb 2005; status: completed.
02
Drugs
prednisolone sodium metasulfobenzoate
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2004-005032-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005032-35.